Hutchmed Reports the US FDA’s Acceptance of Surufatinib’s NDA for Advanced Neuroendocrine Tumors

Shots:

• The NDA is based on two P-III studies of surufatinib in patients with pancreatic and extra-pancreatic NET in China. The anticipated PDUFA date is April 30, 2022
• The same data from the studies will be used to file MAA to the EMA imminently, based on scientific advice from the EMA’s Committee for Medicinal Products for Human Use
• Surufatinib received FTD in Apr’20 and ODD in Nov’19 for the treatment of pancreatic and extra-pancreatic NET. Hutchmed currently retains all rights to surufatinib globally

Click here to­ read full press release/ article | Ref: Hutchmed | Image: Hutchmed